¿ AEterna Laboratories Inc., of Quebec City, Quebec, completed its public offering of about 1.96 million subordinate voting shares at a price of C$8 per share, grossing C$15.7 million (US$10 million). The net proceeds will be used to further fund the clinical development of its lead product, Neovastat, to support additional research and development efforts and for other general corporate purposes, including working capital. (See BioWorld Today, Sept. 5, 2001.)
¿ Biovector Therapeutics SA, of Labhge, France, finalized its process of reorganization to focus on its core business of innovative drug delivery of active drugs using its Biovector Systems. Biovector¿s new management decided to stop the development of proprietary products and instead dedicate its efforts to collaborating with major pharmaceutical players. It now is a subcontractor and supplier of patented technologies to the biopharmaceutical industry.
¿ SRI International, of Menlo Park, Calif., developed a software system that uses artificial intelligence and symbolic computing to better understand and manipulate information produced by genome data. Its software, Pathway Tools, encodes scientific theories for a greater understanding of biological systems, improved scientific collaboration and integration of disparate sources of bioscience knowledge, the company said.